K Pharma

K Pharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of K Pharma (4896.T) as of Oct 17, 2026 is -916.06 M JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -836.35 M JPY — a change of 9.53% (lower).

EBITDA

-916.06 MJPY

YoY

9.53%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of K Pharma is 2025 -916.06 M JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of K Pharma was 2024 -836.35 M JPY. It decreases by 9.53% lower compared to the previous year.

The K Pharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2021
-219.03 M JPY
Jan 1, 2022
-353.77 M JPY
Jan 1, 2023
366.06 M JPY
Jan 1, 2024
-836.35 M JPY
Jan 1, 2025
-916.06 M JPY
The K Pharma EBITDA history
YEAREBITDAYoY
-916.06 MJPY+9.53%
-836.35 MJPY-328.47%
366.06 MJPY-203.47%
-353.77 MJPY+61.52%
-219.03 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

K Pharma Stock analysis

What does K Pharma do? K Pharma Inc is a Japan-based pharmaceutical company headquartered in Minato-ku, Tokyo. The company operates in the Health Care sector, specifically within the Pharmaceuticals industry. It has a small team of 13 full-time employees. K Pharma Inc completed its initial public offering (IPO) on October 17, 2023, with the ticker symbol 4896.T and ISIN JP3280900006. The company's website is https://kpharma.co.jp/. K Pharma Inc focuses on the research, development, manufacture, and sale of pharmaceuticals. It is engaged in the field of induced pluripotent stem cell (iPS) drug discovery, which involves creating neural progenitor cells from iPS cells. These cells are cryopreserved and used in a treatment process where 200,000 cells are transplanted via injection into the spinal cord injury site of patients. The company also conducts research, development, manufacture, and sale of regenerative medicine products. K Pharma Inc operates through a single business segment, concentrating on pharmaceutical and regenerative medicine solutions. The company's activities are centered on developing innovative treatments, particularly in the area of spinal cord injury recovery using stem cell technology. K Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about K Pharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of K Pharma is -916.06 M JPY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of K Pharma changed from -836.35 M JPY to -916.06 M JPY, representing a 9.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) K Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s K Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — K Pharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — K Pharma